Searched for
GLENMARK PHARMA SHARES
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Ahead of Market: 10 things that will decide stock market action on WednesdayNifty 50 and BSE Sensex declined amid selling in banking, auto and IT stocks. Markets remain range-bound, awaiting triggers, with analysts ...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip BandyopadhyayIndian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Two Trades for Today: A pharma major for a 6% upmove, a mid-cap healthcare stock for a gain of about 5%Our technical analysts identify select stocks that may gain momentum even in volatile markets. Here are the technical calls for today.
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Stock Radar: Glenmark Pharma breaks out from a range to hit fresh record high in March 2026; what should investors do?Glenmark Pharma Ltd has broken out of a 7-month consolidation on weekly charts, reaching fresh record highs. Experts suggest short-term tra...
- Glenmark Pharma shares in focus on $1.1 billion deal for oncology drugGlenmark Pharma shares: The company's unit Glenmark Specialty S.A. signed an exclusive licensing deal with China’s Hengrui Pharma for Trast...
- Glenmark Pharma shares in focus after USFDA warning to Indore plantGlenmark Pharmaceuticals disclosed receiving a warning letter from the U.S. FDA for its Indore facility following a February inspection. Th...
- Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...
- Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation playGlenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...
- Stock Radar: Breakout from falling trendline makes Glenmark an attractive buy; check target & stop lossGlenmark Pharma Ltd has broken out of an 8-month consolidation, breaching a downward trendline. Experts suggest a buy for short-to-medium t...
- Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drugGlenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated ...
- Glenmark Pharma shares in focus as company swings back to profit in Q3Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previou...
- Glenmark Pharma shares in focus after 34% stake acquisition in O2 renewable energy XXIVThe acquisition supports Glenmark’s goal of achieving carbon neutrality by 2030. The deal follows a Securities Subscription & Shareholder’s...
- Glenmark Pharma reports 31% drop in net profit to Rs 211 croreGlenmark is ranked 14th with a market share of 2.17% Sales from North America fell 10.2% YoY to Rs 663 crore. Europe sales saw 8% YoY to Rs...
- Buy Glenmark Pharma, target price Rs 560: Yes SecuritiesGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a mid-cap company (with a market cap of Rs 14826.53 crore) operating in ph...
Load More
